India Health Ministry Regulates Stem Cell Therapy
Analysis based on 25 articles · First reported Sep 17, 2026 · Last updated Sep 17, 2026
The advisory tightens India's regulatory framework for stem cell therapy, which is likely to curb unregulated commercial clinics offering unproven autism treatments while reinforcing the approved pathway for legitimate regenerative medicine developers. Listed and private biotech firms with approved CAR-T products such as ImmunoACT and Immuneel Therapeutics stand to benefit from clearer compliance rules, whereas unregulated stem cell service providers face registration cancellation and penalties.
The Bangladesh — Ministry of Health and Family Welfare issued an advisory dated September 16, 2026, to all States and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010, regulating the use of stem cell therapy. The advisory directs that stem cell therapy may be offered as routine standard clinical care only for disease conditions and indications included in the ministry-approved list, and that unproven stem cell interventions must not be offered as routine, standard or commercial clinical services. For Autism Spectrum Disorder, the therapeutic use of any type of stem cell remains restricted to duly approved clinical trials under the National Guidelines for Stem Cell Research, 2017, issued jointly by the India — Indian Council of Medical Research and the India — Department of Biotechnology. The advisory implements the India — Supreme Court of India judgment of January 30, 2026, in Al-Falah Charitable Trust & Ors v Union of India & Ors, which held that unapproved stem cell therapy cannot be offered as a routine or commercial treatment for autism and that non-compliance attracts professional misconduct under Regulation 7.22 of the IMC Regulations, 2002, plus action under Sections 32 and 40 of the Clinical Establishments Act, 2010, including cancellation of registration and penalty. The India — National Medical Commission advisory dated September 5, 2026, reinforced that unauthorized administration, prescription, promotion or advertisement of stem cell therapy beyond approved indications constitutes professional misconduct, and State Medical Councils were asked to examine alleged violations and take disciplinary action. The India — Central Drugs Standard Control Organisation has so far approved two CAR-T cell therapies, NexCAR19 developed by ImmunoACT and Qartemi of Immuneel Therapeutics, for blood cancer patients who have exhausted other treatment options.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard